331 related articles for article (PubMed ID: 27598218)
1. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
2. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
[TBL] [Abstract][Full Text] [Related]
3. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
4. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
5. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
Goodspeed A; Jean A; Costello JC
Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
[TBL] [Abstract][Full Text] [Related]
6. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
7. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
8. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy.
Li H; Yu G; Shi R; Lang B; Chen X; Xia D; Xiao H; Guo X; Guan W; Ye Z; Xiao W; Xu H
Mol Cancer; 2014 Jan; 13():8. PubMed ID: 24423412
[TBL] [Abstract][Full Text] [Related]
10. Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A.
Khandelwal M; Anand V; Appunni S; Seth A; Singh P; Mathur S; Sharma A
Mol Cell Biochem; 2018 Sep; 446(1-2):105-114. PubMed ID: 29368096
[TBL] [Abstract][Full Text] [Related]
11. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
12. Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer.
Tada Y; Yokomizo A; Shiota M; Tsunoda T; Plass C; Naito S
Int J Oncol; 2011 Sep; 39(3):727-33. PubMed ID: 21617853
[TBL] [Abstract][Full Text] [Related]
13. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms.
Li F; Zheng Z; Chen W; Li D; Zhang H; Zhu Y; Mo Q; Zhao X; Fan Q; Deng F; Han C; Tan W
Drug Resist Updat; 2023 May; 68():100938. PubMed ID: 36774746
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
[TBL] [Abstract][Full Text] [Related]
17. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
Viet CT; Dang D; Achdjian S; Ye Y; Katz SG; Schmidt BL
PLoS One; 2014; 9(11):e112880. PubMed ID: 25391133
[TBL] [Abstract][Full Text] [Related]
18. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
[TBL] [Abstract][Full Text] [Related]
19. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Chang YW; Singh KP
PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
[TBL] [Abstract][Full Text] [Related]
20. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
